Janux Therapeutics Stock
Janux Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David Alan Campbell
- Employees
- 113
- Market cap
- $1 B
- IPO
- 11/06/2021
Janux Therapeutics, Inc. is a healthcare company based in San Diego, USA, dedicated to the development of innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently,…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Janux Therapeutics stock: price history
1D
-4.7%
1W
-10.2%
1M
+1.6%
6M
+4.4%
YTD
+19.6%
1Y
-39.3%
2Y
-66.6%
5Y
-21.9%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~17% weaker price swings than usual
Ask the agents about Janux Therapeutics
Analyst assessment of Janux Therapeutics
PRICE TARGET LOW
US$14.00
CONSENSUS
US$30.14
MEDIAN
US$26.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
12
BUY
3
HOLD
1
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 24/08/2026
Janux Therapeutics stock metrics
P/E
-10.01
P/B
1.12
EV/EBITDA
-9.96
RETURN ON EQUITY
-2.4%
NET MARGIN
-214.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.6%
FLOAT SHARES
57,830,155
AVG. DAILY VOLUME (30D)
905,365
Insider transactions (SEC)
Campbell David Alan
Campbell David Alan
DOBMEIER ERIC
CAPPS VICKIE L
Barrett Ronald W
Institutional holders
Comparable stocks
Frequently asked questions about Janux Therapeutics stock
What does Janux Therapeutics do?
Janux Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David Alan Campbell, the company employs around 113 people.
The IPO was on 11/06/2021; the stock trades on NASDAQ under the ticker JANX.
What do analysts say about Janux Therapeutics stock?
16 analysts rate the stock, the consensus is Buy (as of 24/08/2026).
The average price target is US$30.14, ranging from US$14.00 to US$55.00, with a median of US$26.00.
This is an external assessment, not a statement by Market Jury.
When does Janux Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Janux Therapeutics pay a dividend?
No, Janux Therapeutics currently does not pay a dividend.
Which stocks are comparable to Janux Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Janux Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Janux Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.